Skip to content

A modified Percutaneous Transhepatic Variceal Embolization with tissue adhesive in esophageal variceal bleeding management

A modified Percutaneous Transhepatic Variceal Embolization with tissue adhesive in esophageal variceal bleeding management

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-TNRC-08000205
Enrollment
Unknown
Registered
2008-11-27
Start date
2002-10-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Cirrhosis

Interventions

The experimental group (a modified PTVE):The patients was performed PTVE by venipuncture, intubation tube, visualization, 2-OCA was then injected continuously until all the varices in lower esophagus
The control group (traditional embolotherapy):The patients was performed PTVE as the experimental group, vena coronaria ventriculi, vena gastrica posterior or short gastric veins was injected absolute

Sponsors

Shandong Provincial Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
7 Years to 84 Years

Inclusion criteria

Inclusion criteria: 1. cirrhotic patients with acute or recent (within 3 months) esophageal or gastric variceal hemorrhage; 2. cirrhotic patients was confirmed with the laboratory and imageology data; 3. the degree of gastroesophageal varices was F2 or F3 in these patients, as revealed by gastroendoscopy; 4. computerized tomography (CT) portal venography was performed for detection of variceal afferent veins before operation; 5. giving the consent to complete Preoperative check and postoperative recheck.

Exclusion criteria

Exclusion criteria: 1. association with hepatocellular carcinoma or other malignancy; 2. complete obstruction of the portal vein due to thrombosis; 3. grave hypertension, coronary heart disease, or impaired function of cardiorespiratory; 4. encephalopathy greater than stage II; severe jaundice with serum bilirubin more than 100 mg L-1; 5. presence of hepato-renal syndrome or chronic renal insufficiency; 6.obvious hemorrhagic tendency, PT>25s; 7. The portal vein was failure to venous cannula with kinds of cause; 8. inability or refusal to give the consent to complete preoperative check and postoperative recheck.

Design outcomes

Primary

MeasureTime frame
UGI rebleeding;Survival rate;Varices relapse;Varices eradication;Arrest of acute bleeding;

Secondary

MeasureTime frame
The improving of clinical symptom;Complication;portal vein image;Liver functional assessment;The quality of life;

Countries

China

Contacts

Public ContactZhang Chunqing
zhchqing@medmail.com.cn+86 13583188661

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026